RxDoctor Payments Data

Linda Morehouse, DO

Endocrinology, Diabetes & Metabolism · Citrus Heights, CANPI 1588921910

Payments from drug & device makers

$536in general payments, 2019–2025

Across 30 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$118
  • Tandem Diabetes Care, Inc.$84
  • Medtronic$83
  • Novo Nordisk$47
  • AbbVie$38
  • Amgen$33
  • plus $132 from 7 others

What the payments were for

  • Food & beverage$536100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$536 in reported general payments places this provider in the 35th percentile of 952 endocrinology, diabetes & metabolism providers in California.

See all endocrinology, diabetes & metabolism providers in California

Medicare billing

Part B allowed, 2024
$156,879
Medicare patients
335
Services billed
4,030

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide91$105,304
OzempicSemaglutide67$82,980
RybelsusSemaglutide45$57,455
JardianceEmpagliflozin40$48,385
TrulicityDulaglutide34$46,534
JanuviaSitagliptin Phosphate32$37,651
Tresiba Flextouch U-200Insulin Degludec22$24,219
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$18,743
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$13,360
Humalog Kwikpen U-100Insulin Lispro37$10,499
Fiasp FlextouchInsulin Aspart (Niacinamide)14$10,254
Lantus SolostarInsulin Glargine,hum.Rec.Anlog60$8,456
Nano 2nd Gen Pen NeedlePen Needle, Diabetic42$4,959
HumalogInsulin Lispro12$4,577
Novolin 70-30 FlexpenInsulin Nph Hum/Reg Insulin Hm15$1,524

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro$118$157,136150 claims
Novo NordiskOzempic, Rybelsus$47$140,434112 claims
Boehringer IngelheimJardiance$23$48,38540 claims
AbbVieSynthroid$38$86914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 952 endocrinology, diabetes & metabolism providers in California.

Other endocrinology, diabetes & metabolism in Citrus Heights

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →